Flagship Pioneering, LLC Long-Term Concentrated

CIK: 0001400240 · Show all filings

Period: Q4 2023 (← Previous) (Next →)

Filing Date: Feb 14, 2024

Total Value ($000): $1,325,312 (100.0% shares, 0.0% debt)

Holdings (7)

MRNA Moderna Inc 72.5%

Value ($000) $961,287 Shares 9,666,038 Est. Cost $16.43 Unrealized +411.8%

SANA Sana Biotechnology Inc 7.7%

Value ($000) $102,008 Shares 25,001,856 Est. Cost $32.56 Unrealized -88.7%

— Omega Therapeutics Inc 6.6%

Value ($000) $87,969 Shares 29,225,579 Est. Cost $17.39 Unrealized —

FHTX Foghorn Therapeutics Inc 6.2%

Value ($000) $81,748 Shares 12,674,120 Est. Cost $19.16 Unrealized -77.5%

DNLI Denali Therapeutics Inc 3.8%

Value ($000) $49,787 Shares 2,319,968 Est. Cost $17.97 Unrealized +10.2%

— Seres Therapeutics Inc 2.4%

Value ($000) $32,434 Shares 23,117,045 Est. Cost $7.75 Unrealized —

SYRS Syros Pharmaceuticals Inc 0.8%

Value ($000) $10,079 Shares 1,293,848 Est. Cost $7.03 Unrealized -51.3%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
MRNA	Moderna Inc	9,666,038	$961,287	72.5%	$16.43	+411.8%	COM	60770K107
SANA	Sana Biotechnology Inc	25,001,856	$102,008	7.7%	$32.56	-88.7%	COM	799566104
—	Omega Therapeutics Inc	29,225,579	$87,969	6.6%	$17.39	—	COM	68217N105
FHTX	Foghorn Therapeutics Inc	12,674,120	$81,748	6.2%	$19.16	-77.5%	COM	344174107
DNLI	Denali Therapeutics Inc	2,319,968	$49,787	3.8%	$17.97	+10.2%	COM	24823R105
—	Seres Therapeutics Inc	23,117,045	$32,434	2.4%	$7.75	—	COM	81750R102
SYRS	Syros Pharmaceuticals Inc	1,293,848	$10,079	0.8%	$7.03	-51.3%	COM	87184Q206